Johns Hopkins recently received approval from the United Network for Organ Sharing to be the first hospital in the United States to perform HIV-positive to HIV-positive organ transplants. The institution will be the first in the nation to do an HIV-positive kidney transplant and the first in the world to execute an HIV-positive liver transplant.
09 February 2016 | Johns Hopkins Medicine
In a Federal Register notice on Nov. 25, 2015, the U.S. Department of Health and Human Services published safeguards and criteria for research to assess the safety and effectiveness of solid organ transplantation from donors with HIV infection to recipients with HIV infection.
27 November 2015 | National Institutes of Health
Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.
12 October 2015 | Monthly Prescribing Reference
A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.
04 September 2015 | HIVandHepatitis.com
The US Department of Health and Human Services (HHS) has unveiled new regulations to establish a parallel system of organ donation intended to serve patients with the human immunodeficiency virus (HIV).
11 May 2015 | Regulatory Affairs Professionals Society
Kidney transplant patients with HIV have similar survival rates as those without HIV, a new study finds. The study included 510 HIV-positive adults who had kidney transplants in the United States between 2002 and 2011. Overall, these patients had similar five- and 10-year survival rates as kidney transplant patients without HIV.
20 March 2015 | U.S. News & World Report
Men and women without HIV infection who use tenofovir-based pre-exposure prophylaxis (PrEP) develop significant but not clinically relevant declines in kidney function, according to the largest study to date to look at the issue.
26 December 2014 | Medscape (requires free registration)
HIV-infected adults are at a higher risk for developing heart attacks, kidney failure and cancer. But, contrary to what many had believed, the researchers say these illnesses are occurring at similar ages as adults who are not infected with HIV.
10 December 2014 | Science Daily
Abnormal kidney biomarkers are common but rarely progress to serious kidney dysfunction in HIV positive people taking tenofovir, and longer duration of use, older age, and having diabetes or high blood pressure raise the risk, researchers reported at IDWeek 2014 last week in Philadelphia. A related study found that people with low body weight experienced progressive kidney function decline while taking tenofovir.
20 October 2014 | HIVandhepatitis.com
Gilead is running nine phase III studies involving tenofovir alafenamide (TAF), which reflects the importance of the drug to Gilead's future HIV business. It is collecting an enormous amount of clinical data in which to make the case that TAF should be a preferred backbone drug for new and existing HIV patients, as well as patients who cannot use Viread because of pre-existing kidney conditions.
23 September 2014 | The Street